SCHEMBL5462248

SCHEMBL5462248

COC(=O)c1cc(/C=C2/SC(=O)N(Cc3cc(Cl)cc(Cl)c3)C2=O)ccc1O

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 3/20 0.58
▸ ACP1 P24666 3/20 0.58
▸ ENPP2 Q13822 2/20 0.51
▸ PTPN22 Q9Y2R2 3/20 0.51
▸ PPARG P37231 4/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ MAPT P10636 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ ATM Q13315 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ BAG3 O95817 1/20 0.49
▸ ALOX5 P09917 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5462250 1.00 PTPN1 (0.58) PTPN1ACP1ENPP2PTPN22PPARG
SCHEMBL5470315 0.89 PTPN1 (0.56) PTPN1ACP1ENPP2PTPN22PPARG
SCHEMBL5470321 0.89 PTPN1 (0.56) PTPN1ACP1ENPP2PTPN22PPARG
SCHEMBL5463880 0.88 PTPN1 (0.60) PTPN1ACP1ENPP2PTPN22PPARG
SCHEMBL5463879 0.88 PTPN1 (0.60) PTPN1ACP1ENPP2PTPN22PPARG
SCHEMBL5461849 0.86 PTPN22 (0.51) PTPN1ACP1ENPP2PTPN22PPARG
SCHEMBL5461851 0.86 PTPN22 (0.51) PTPN1ACP1ENPP2PTPN22PPARG
SCHEMBL5462526 0.84 MEN1 (0.56) PTPN1ACP1ENPP2MEN1ALDH1A1
SCHEMBL5462529 0.84 MEN1 (0.56) PTPN1ACP1ENPP2MEN1ALDH1A1
SCHEMBL5462792 0.83 PTPN1 (0.70) PTPN1ACP1ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 PTPN1 3264/4885ACP1 254/4885ENPP2 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback